Scientists Create New Cancer-Killing Tool Using CRISPR

Scientists just figured out how to make cancer cells destroy themselves from the inside out.

A team led by Nobel laureate Jennifer Doudna at UC Berkeley and the Gladstone Institute discovered a way to program CRISPR technology to hunt down and kill cancer cells with specific mutations. Their tool targets the RNA messages that cancer cells produce, triggering a self-destruct sequence that shreds the cell's DNA.

The breakthrough tackles one of cancer treatment's biggest challenges. About 40 to 50 percent of cancers involve mutations in a protein called p53, which normally stops tumors from growing. When p53 goes rogue, it becomes nearly impossible to target with traditional drugs because the mutated protein lacks the usual binding sites that medications need to work.

Current treatments simply can't reach these "undruggable" mutations. Chemotherapy and radiation attack all rapidly dividing cells, harming healthy tissue alongside tumors. Even targeted therapies need specific molecular hooks that many cancer mutations don't have.

The new approach works differently. Researchers modified a CRISPR protein called Cas12a2 to recognize the unique RNA signatures that mutated cancer cells produce. When the programmed tool finds its target, it activates and begins shredding chromatin, the packaged form of DNA inside cells. This triggers damage responses that ultimately kill the cancer cell while leaving healthy cells untouched.

The team tested their system on cancer cells in the laboratory and found it selectively destroyed cells carrying the targeted mutations. Unlike gene editing, which permanently alters DNA, this method acts more like a smart bomb that activates only in the presence of specific cancer signatures.

The Ripple Effect

This discovery extends beyond p53 mutations. The same approach could theoretically target any cancer producing distinctive RNA messages, potentially opening treatment options for thousands of patients whose tumors currently have no effective therapies.

The research builds on CRISPR's growing medical toolkit. What started as a gene-editing technology now shows promise as a precision weapon against diseases that seemed untouchable just years ago. Multiple research institutions collaborated on this work, including teams from the University of Utah, Utah State University, and the Francis Crick Institute in London.

While the technology needs more development before human trials, the proof of concept offers genuine hope. Researchers are already exploring ways to deliver the system safely to tumors in living patients and fine-tuning it to recognize additional cancer signatures.

For the estimated millions of people diagnosed with cancers carrying undruggable mutations each year, this represents the first real possibility of a treatment designed specifically for their disease.

Science just gave cancer cells a new reason to worry.